ClinicalTrials.gg
Active, not recruitingNCT07260695Updated Oct 26, 2026

Odyssey Evaluation in Post LASIK Patients

A Phase 4 interventional study of Odyssey intraocular lens in Cataract, sponsored by Center For Sight. Active, not recruiting at 1 site in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Center For Sight · Phase 4, Interventional, and Treatment

How we know

Updated Oct 26, 2026Now Active, not recruitingPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 456 studies in Cataract with a site in United States — 49 open to participants now, 56 under way, 4 of them phase 3. Cataract · United States.

Enrollment
257th of 322
30 · median 100
Started
2025
with 23 others
Phase 4
86 of 456
7 open now
Primary completion
2026-12
later than 25 of 54 live
Registered
418th of 456
by date

Among the 456 studies in Cataract with a site in United States, this one is the 257th largest by enrollment of the 322 interventional ones that give a count, is one of 24 that started in 2025, is one of 86 in phase 4, reaches primary completion later than 25 of the 54 other live ones, and was the 418th registered.

Cataract

1,633 studies on the registry are indexed under Cataract; 234 are open to participants now.

Browse Cataract studies →

Open to participants now

49 of the 456 studies in Cataract with a site in United States are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 143 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 456 studies in Cataract with a site in United States, or all of them as a file.
02

Study summary

This prospective study evaluates the visual and refractive outcomes of the TECNIS Odyssey intraocular lens (IOL) implanted in patients with a history of myopic LASIK. Given the unique optical challenges of post-LASIK eyes, including altered corneal curvature and higher-order aberrations, the study aims to assess the IOL's performance in terms of distance, intermediate, and near vision, and patient satisfaction. Its design features may offer favorable outcomes in these patients.

03

Conditions studied

  • Cataract

Browse trials for

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects MUST fulfill the following conditions to qualify for enrollment into the trial

  1. Age: 50 years and older.
  2. Gender: Males and Females.
  3. Bilateral cataracts
  4. Bilateral implantation of Odyssey IOLs (toric and non-toric)
  5. Scheduled to undergo standard cataract surgery in both eyes, within 1 to 30 days between surgeries.
  6. Willing and able to provide written for participation in the study.
  7. Willing and able to comply with scheduled visits and study examination procedures.
  8. Postoperative best corrected visual acuity of 0.2 logMAR (20/32 Snellen) or better in each eye.

Exclusion criteria

Exclusion Criteria:

Subjects with ANY of the following conditions on the eligibility exam may NOT be enrolled into the trial.

  1. Established ocular pathology, including: glaucoma (except glaucoma suspects), uveitis, and clinically-significant retinal pathology affecting the macula (with visual acuity worse than 20/25) and/or any other ocular findings that may, in the opinion of the investigator, affect vision.
  2. Uncontrolled diabetes.
  3. Use of any systemic or topical drug known to interfere with visual performance.
  4. Any concurrent infectious/non-infectious conjunctivitis, keratitis or uveitis.
  5. corneal dystrophy.
  6. Contact lens use during the active treatment portion of the trial.
  7. Irregular astigmatism.
  8. Corneal irregularities potentially affecting visual acuity (i.e., keratoconus, corneal opacities
  9. History of chronic intraocular inflammation.
  10. History of retinal detachment.
  11. Pseudoexfoliation syndrome or any other condition that has the potential to weaken the zonules.
  12. Previous intraocular surgery.
  13. Previous keratoplasty
  14. Previous refractive surgery other than myopic LASIK or PRK (i.e., radial keratotomy, hyperopic LASIK, etc)
  15. Severe dry eye.
  16. Pupil abnormalities.
  17. Subject who may reasonably be expected to require a secondary surgical intervention at any time during the study (other than YAG capsulotomy, i.e., LASIK).
  18. Any clinically significant, serious, or severe medical or psychiatric condition that may interfere with the interpretation of study results.
  19. Participation in (or current participation) any ophthalmic drug or ophthalmic device trial within the previous 30 days prior to the start date of this trial.
  20. Inability to focus or fixate for prolonged periods of time (e.g., due to strabismus, nystagmus, etc.)
  21. Abnormal iris

The principal investigator reserves the right to declare a patient ineligible or non-evaluable based on medical evidence that indicates the patient is unsuitable for the trial.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Other
    Odyssey IOL

    Device: Odyssey intraocular lens

Interventions

  • DeviceOdyssey intraocular lens

    The Odyssey intraocular lens is intended to be implanted at the time of cataract surgery to replace the natural lens.

06

What researchers measure

Primary outcomes

  1. Binocular defocus curve

    The defocus curve assesses a patient's visual performance at various distances by introducing different levels of lens defocus (measured in diopters) and recording the corresponding visual acuity. It provides a comprehensive evaluation of the range of clear vision (distance, intermediate, and near) offered by an intraocular lens.

    Time frame: 3 months postoperatively

Secondary outcomes

  1. Patient satisfaction

    Percentage of patients who reported being completely, mostly, moderately, a little or not at all satisfied with overall vision

    Time frame: 3 months postoperatively

  2. Spectacle independence at near.

    Percentage of patients who reported wearing glasses none of the time or a little of the time for near activities (16 inches/40 cm).

    Time frame: 3 months postoperatively

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Dec 2026, 16 months after the start.

Of 40 non-industry phase 4 interventional studies under Cataract, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 39. This study's planned 16 months is below that.

Counting every sponsor, half of 47 studies reached it within 20 months; a quarter within 11 and three quarters within 34.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Aug 2026 → Dec 2026 and completion Aug 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2025
First posted
Dec 3, 2025
StartActual
Aug 18, 2025
Primary completionEst.
Dec 18, 2026was Aug 2026
CompletionEst.
Dec 18, 2026was Aug 2026
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 26, 2026
Primary completion
Aug 18, 2026→Dec 18, 2026
Oct 26, 2026
Study completion
Aug 18, 2026→Dec 18, 2026
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Recruiting→Active, not recruiting
    Primary completion Aug 18, 2026→Dec 18, 2026
    Study completion Aug 18, 2026→Dec 18, 2026
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07260695
Lead sponsor
Center For Sight
Collaborators
Sengi Clinical
Responsible party
Sponsor
First posted
Dec 3, 2025
Start date
Aug 18, 2025
Primary completion
Dec 18, 2026 (estimated)
Completion
Dec 18, 2026 (estimated)
Last update
Oct 26, 2026

Study contacts

Joaquin K De Rojas, MD
principal investigator · Center For Sight

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion